This handbook is the first comprehensive book of its kind reviewing the clinically relevant current status of tissue kallikrein and kallikrein-related peptidases research. Since several members of the KLK family are key players in (patho-)physiological processes, structural, functional, and regulatory studies are under way to develop new strategies to prevent and treat disorders to which individual members of the KLK protease family contribute significantly. The goal of this book is to inform clinicians, physician scientists and researchers about the prominent role of the multifaceted and interactive KLK system in normal physiology and pathological organ function.
Inhaltsverzeichnis
1;Preface;5 2;List of contributing authors;7 3;Table of Contents;11 4;Introduction to Volume 1: Kallikrein-related Peptidases. Characterization, Regulation, and Interactions Within the Protease Web;19 4.1;Bibliography;21 5;1 Genomic Structure of the KLK Locus;23 5.1;1.1 Introduction;23 5.2;1.2 Kallikreins in rodents;24 5.2.1;1.2.1 The mouse kallikrein gene family;25 5.2.2;1.2.2 The rat kallikrein gene family;26 5.3;1.3 Characterization and sequence analysis of the human KLK gene locus;27 5.3.1;1.3.1 Locus overview;27 5.3.2;1.3.2 Repeat elements and pleomorphism;29 5.4;1.4 Structural features of the human KLK genes and proteins;30 5.4.1;1.4.1 Common structural features;30 5.5;1.5 Sequence variations of human KLK genes;31 5.6;1.6 Regulation of KLK activity;32 5.6.1;1.6.1 At the mRNA level;32 5.6.2;1.6.2 Locus control of KLK expression;33 5.6.3;1.6.3 Epigenetic regulation of KLK gene expression;35 5.7;1.7 Isoforms and splice variants of human KLKs;36 5.8;1.8 Evolution of KLKs;39 5.9;Bibliography;40 6;2 Single Nucleotide Polymorphisms in the Human KLK Locus and Their Implication in Various Diseases;49 6.1;2.1 Introduction;49 6.2;2.2 KLKSNPs - data-mining from SNPdb and 1000 Genomes;50 6.3;2.3 Functional annotations using web-based prediction tools;52 6.4;2.4 Experimentally validated functional KLK SNPs;53 6.5;2.5 KLKSNP haplotypes and tagging;54 6.6;2.6 Malignant and non-malignant diseases and association with KLK SNPs;56 6.6.1;2.6.1 Association studies on high-risk variants in KLK genes;57 6.6.2;2.6.2 Association studies on low-risk variants in KLK genes;57 6.7;2.7 Conclusions;89 6.8;Bibliography;89 7;3 Evolution of Kallikrein-related Peptidases;97 7.1;3.1 Introduction;97 7.2;3.2 Basic elements of phylogenetic analysis;98 7.3;3.3 Evolutionary trends at the KLK locus;98 7.4;3.4 Evolution of the KLK1-KLK4 sublocus;100 7.4.1;3.4.1 KLK2 and KLK3 originate from a duplicated segment containing both KLK1 and KLK15;100 7.4.2;3.4.2 A large number of KLK1 tandem repeats in the h
ouse mouse;103 7.4.3;3.4.3 The rat KLK1 sublocus consists of 10 large repeats;105 7.4.4;3.4.4 Four duplications of KLK1 and KLK15 in the dog;106 7.4.5;3.4.5 A large repeat containing KLK4 in the horse;108 7.5;3.5 KLK genes in non-mammalian species;110 7.6;3.6 General conclusions and remarks on the evolution of KLK genes;111 7.7;Bibliography;112 8;4 Structural Aspects of Kallikrein-related Peptidases;115 8.1;4.1 Introduction;115 8.2;4.2 Individual KLK structures;116 8.2.1;4.2.1 Tissue kallikrein (KLK1);116 8.2.2;4.2.2 Prostate specific antigen (PSA/KLK3);118 8.2.3;4.2.3 Prostase (KLK4);119 8.2.4;4.2.4 Stratum corneum tryptic enzyme (SCTE/KLK5);122 8.2.5;4.2.5 Myelencephalon-specific protease or neurosin (MSP/KLK6);124 8.2.6;4.2.6 Stratum corneum chymotryptic enzyme (SCCE/KLK7);126 8.2.7;4.2.7 Neuropsin (KLK8);128 8.2.8;4.2.8 Other mammalian KLK structures;129 8.3;Bibliography;130 9;5 Molecular Recognition Properties of Kallikrein-related Peptidases on Synthetic and Endogenous Substrates;135 9.1;5.1 Introduction;135 9.2;5.2 Substrate specificities of individual kallikrein-related peptidases;139 9.2.1;5.2.1 The classical kallikreins (KLK1, KLK2, KLK3);139 9.2.2;5.2.2 KLK4/KLK5/KLK7;143 9.2.3;5.2.3 KLK6/KLK13/KLK14;145 9.2.4;5.2.4 KLK8/KLK10/KLK12;147 9.2.5;5.2.5 KLK9/KLK11/KLK15;148 9.3;Bibliography;150 10;6 Natural, Engineered and Synthetic Inhibitors of Kallikrein-related Peptidases;159 10.1;6.1 Introduction;159 10.2;6.2 KLK diversity;159 10.3;6.3 The KLK superfamily: Structure and catalytic mechanism;159 10.4;6.4 KLK inhibition: Rationale and mechanisms;161 10.5;6.5 Proteinaceous inhibitors;162 10.5.1;6.5.1 Kunitz domain inhibitors;162 10.5.2;6.5.2 Kazal domain inhibitors;164 10.5.3;6.5.3 Other canonical inhibitors;165 10.5.4;6.5.4 Serpins;165 10.6;6.6 Naturally occurring small molecule kallikrein inhibitors;166 10.7;6.7 Engineered KLK Inhibitors;167 10.7.1;6.7.1 Approaches to inhibitor design;168 10.7.2;6.7.2 Pharmacological challenges for therapeutic inhibitors;16
8 10.7.3;6.7.3 Serpins;168 10.7.4;6.7.4 Ecotin;169 10.7.5;6.7.5 Sunflower Trypsin Inhibitor (SFTI);170 10.7.6;6.7.6 Warhead inhibitors;171 10.8;6.8 Conclusions and outlook;172 10.9;Acknowledgements;172 10.10;Bibliography;172 11;7 Kallikrein-related Peptidases as Pharmaceutical Targets;179 11.1;7.1 Introduction;179 11.2;7.2 KLK disease markers as potential therapeutic targets;180 11.3;7.3 KLKs in oncology;183 11.3.1;7.3.1 Prostate cancer;183 11.3.2;7.3.2 Ovarian and pancreatic cancer;185 11.4;7.4 KLKs in inflammatory skin diseases;187 11.4.1;7.4.1 Kallikrein expressions and activities in skin;187 11.4.2;7.4.2 Netherton Syndrome as most relevant clinical model;188 11.4.3;7.4.3 Atopic dermatitis, the potential major indication for kallikrein targeting;189 11.4.4;7.4.4 Psoriasis and relevance of kallikreins;190 11.4.5;7.4.5 Other potential skin disorders with kallikrein involvement;190 11.5;7.5 KLKs in neurological disorders;191 11.5.1;7.5.1 Alzheimers disease and dementia;191 11.5.2;7.5.2 Multiple sclerosis (MS);191 11.6;7.6 Kallikrein inhibitors to treat human diseases;192 11.6.1;7.6.1 Design of KLK inhibitors and clinical development;192 11.6.2;7.6.2 KLK inhibitors in oncology;194 11.6.3;7.6.3 KLK inhibitors in dermatology;197 11.7;7.7 Conclusions and Outlook;198 11.8;Bibliography;199 12;8 Expression of Kallikrein-related Peptidases under (Patho-)Physiological Conditions;205 12.1;8.1 Introduction;205 12.2;8.2 KLK expression in tissues and biological fluids under physiological conditions;206 12.2.1;8.2.1 KLKs in the central and peripheral nervous system;206 12.2.2;8.2.2 KLKs in the female reproductive system;210 12.2.3;8.2.3 KLKs in the male reproductive system;214 12.2.4;8.2.4 Cellular distribution of KLKs in the gastrointestinal system;216 12.2.5;8.2.5 KLKs in the skin and skin appendages;221 12.2.6;8.2.6 KLKs in the respiratory system;225 12.2.7;8.2.7 KLKs in the urinary system;225 12.2.8;8.2.8 KLKs in lymphatic and endocrine organs (adrenal glands, thyroid gland,
parathyroid glands, pituitary gland);225 12.2.9;8.2.9 KLKs in the cardiovascular system;229 12.2.10;8.2.10 KLKs in the skeletomuscular system;229 12.3;8.3 Expression of KLKs in non-malignant diseases;230 12.3.1;8.3.1 Non-malignant diseases of the CNS;230 12.3.2;8.3.2 Inflammatory-related conditions;233 12.4;8.4 Expression of KLKs in cancer tissues;235 12.4.1;8.4.1 Cancers of the brain;240 12.4.2;8.4.2 Cancers of the female reproductive system;240 12.4.3;8.4.3 Cancers of the male reproductive system;241 12.4.4;8.4.4 Cancers of the gastrointestinal system;242 12.4.5;8.4.5 Cancers of the skin;243 12.4.6;8.4.6 Lung cancer;244 12.4.7;8.4.7 Cancers of the urinary system;244 12.5;8.5 Conclusion;245 12.6;Abbreviations;245 12.7;Bibliography;246 13;9 Kallikrein-related Peptidases within the Proteolytic Web;269 13.1;9.1 Introduction;269 13.2;9.2 KLKs as actors and targets during the initiation and amplification of extracellular proteolytic activity;270 13.2.1;9.2.1 The KLK-dependent KLK activome;270 13.2.2;9.2.2 Cross- and reciprocal activation of KLK and non-KLK proteases;274 13.2.3;9.2.3 Inactivation of protease inhibitors;278 13.3;9.3 KLKs in the termination of proteolytic activity;278 13.3.1;9.3.1 Proteolytic inactivation of (non-)KLK proteases;278 13.3.2;9.3.2 Processing of the uPA receptor;279 13.3.3;9.3.3 Disarming of the proteinase-activated receptors;280 13.4;9.4 Conclusion;281 13.5;Bibliography;282 14;10 Kallikrein-Kinin Cascade: Bioregulation by Human Tissue Kallikrein 1 (hK1, KLK1);289 14.1;10.1 Discovery of classical (true) tissue kallikrein and kinins;289 14.2;10.2 Cellular localization;290 14.3;10.3 Genomics and molecular structure;291 14.4;10.4 Inhibitors of hK1;294 14.5;10.5 Modulation of membrane receptors;295 14.6;10.6 Epigenetic regulation;295 14.7;10.7 Kinin receptors and signaling;296 14.7.1;10.7.1 Receptor subtypes;296 14.7.2;10.7.2 Kinin receptor signaling;297 14.7.3;10.7.3 Regulation of kinin receptor signaling;298 14.8;10.8 Human disease;299 14.8.1;10
.8.1 Hypertension and renal damage;299 14.8.2;10.8.2 Cardiac protection;301 14.8.3;10.8.3 Inflammation and neutrophil function;301 14.8.4;10.8.4 Cancer;304 14.8.5;10.8.5 Angiogenesis;304 14.9;10.9 Conclusion;305 14.10;Abbreviations;306 14.11;Bibliography;307 15;11 Role of KLK4 in Dental Enamel Formation;313 15.1;11.1 Introduction;313 15.2;11.2 Early studies implicated proteases in dental enamel formation;313 15.3;11.3 Investigations of enamel proteases discovered KLK4;314 15.4;11.4 KLK4 and amelogenesis imperfecta;315 15.5;11.5 Klk4 lacZ/lacZ mice;315 15.6;11.6 Other enamel specific genes;320 15.7;11.7 Role of KLK4 in enamel formation;322 15.8;11.8 Conclusion;325 15.9;Bibliography;325 16;12 Kallikrein-related Peptidases and Semen;329 16.1;12.1 Introduction;329 16.2;12.2 Expression pattern and origin of seminal KLKs;330 16.3;12.3 Physiological function of seminal KLKs;330 16.3.1;12.3.1 Seminal coagulation and fibrinolytic balance;330 16.3.2;12.3.2 Sperm motility;332 16.3.3;12.3.3 Reproductive immune interactions;334 16.4;12.4 Proteolytic pathways of seminal KLKs;336 16.4.1;12.4.1 Role of seminal zinc;337 16.4.2;12.4.2 Role of seminal KLK inhibitors;337 16.4.3;12.4.3 Other inhibitory mechanisms of seminal KLKs;338 16.4.4;12.4.4 Seminal proteolytic activation cascade;339 16.5;12.5 Conclusions and outlook;340 16.6;Abbreviations;341 16.7;Bibliography;341 17;13 Kallikrein-related Peptidases and Inhibitors of the Skin;347 17.1;13.1 Introduction;347 17.2;13.2 KLKs in the epidermis;349 17.3;13.3 Desquamation;350 17.4;13.4 Regulation of protease activity;351 17.4.1;13.4.1 KLK activation;351 17.4.2;13.4.2 KLK inhibitors;352 17.5;13.5 Skin disorders;355 17.6;13.6 Conclusions and outlook;358 17.7;Bibliography;359 18;14 Physiological and Pathophysiological Roles of Kallikrein-related Peptidases in the Central Nervous System;367 18.1;14.1 Introduction;367 18.2;14.2 KLK expression and roles in CNS physiology;367 18.2.1;14.2.1 KLK expression in the CNS;367 18.2.2;14.2.2 Physiologica
l roles of KLKs in the CNS;371 18.2.3;14.2.3 Pathophysiological roles of KLKs in the CNS;377 18.3;14.3 Conclusions and outlook;381 18.4;Acknowledgements;382 18.5;Abbreviation;382 18.6;Bibliography;382 19;15 Kallikrein-related Peptidases (KLKs), Proteinase-mediated Signaling and Proteinase-activated receptors (PARs);391 19.1;15.1 Proteinases: shocktroops ofthe innate immune response;391 19.2;15.2 Multiple mechanisms for proteinase-mediated signaling;392 19.3;15.3 Proteinases and PAR-mediated signaling;394 19.4;15.4 Linking PARs to the KLKs: the prostate connection;396 19.5;15.5 Proteolytic cascades, KLKs and the innate immune response;397 19.6;15.6 KLKs, other serine proteinases, PARs and inflammation;397 19.7;15.7 KLKs, PARs and inflammation of the central nervous system and the skin;398 19.8;15.8 KLKs, PARs and cancer;400 19.9;15.9 KLKs and PARs: Therapeutic targets for inflammatory diseases, cancer and other disorders;401 19.10;15.10 Blocking proteinase-mediated PAR activation: PAR-targeted blocking antibodies versus proteinase inhibitors;405 19.11;15.11 Summary and outlook for the future;407 19.12;Acknowledgements;407 19.13;Bibliography;408 20;Index;417